Transgene Announces Financial Calendar for 2014

STRASBOURG, France--()--Regulatory News:

Transgene SA (Paris:TNG) (NYSE-Euronext: TNG) today announced its financial reporting dates for 2014:

March 26, 2014:

  2013 Fiscal Year Results
 

April 22, 2014:

First Quarter 2014 Financial Results
 

June 18, 2014:

Annual Shareholders' Meeting
 

September 10, 2014:

First Half 2014 Financial Results
 

October 21, 2014:

Third Quarter 2014 Financial Results

About Transgene:

Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of oncology and infectious diseases. Transgene’s programs utilize well-tolerated viruses with the goal of indirectly or directly killing infected or cancerous cells. The Company’s four clinical-stage programs are: TG4010 for non-small cell lung cancer; Pexa-Vec for liver cancer; TG4001 for oropharyngeal cancer (under a collaboration agreement with the EORTC) and TG4040 for chronic Hepatitis C. Transgene has concluded corporate strategic agreements for the development of two of its immunotherapy products: an exclusive option agreement with Novartis for the development and commercialization of TG4010 and an in-licensing agreement with U.S.-based Jennerex, Inc. for the development and commercialization of Pexa-Vec in certain territories. The Company also has several programs in research and pre-clinical development that are based on its core viral vector technology. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. Additional information about Transgene is available at www.transgene.fr.

Société anonyme au capital de 72.886.317 € – R.C. Strasbourg B 317 540 581
400 boulevard Gonthier d’Andernach – Parc d’Innovation - CS80166 – 67405 ILLKIRCH GRAFFENSTADEN CEDEX (France)
Tél : + 33 (0)3 88 27 91 00

Contacts

Transgene:
Elisabetta Castelli, +33 (0)3 88 27 91 21
Director IR
or
Laurie Doyle, +1 (339) 832 0752
Director IR US & Corporate Communications
investorrelations@transgene.fr
or
For media: MC Services
Raimund Gabriel, +49 89 210 228 30
raimund.gabriel@mc-services.eu
or
Shaun Brown, +44 207 148 5998
shaun.brown@mc-services.eu

Sharing

Contacts

Transgene:
Elisabetta Castelli, +33 (0)3 88 27 91 21
Director IR
or
Laurie Doyle, +1 (339) 832 0752
Director IR US & Corporate Communications
investorrelations@transgene.fr
or
For media: MC Services
Raimund Gabriel, +49 89 210 228 30
raimund.gabriel@mc-services.eu
or
Shaun Brown, +44 207 148 5998
shaun.brown@mc-services.eu